Search Results
BRUIN trial: LOXO-305 for B-cell malignancies
Efficacy and tolerability results from a Phase I/II study of LOXO-305 in B-cell malignancies
LOXO-305 as a novel treatment in previously treated NHL: results from the BRUIN trial
LOXO-35: a next gen BTK inhibitor for B-cell malignancies
BRUIN: pirtobrutinib shows efficacy for Richter's transformation
BRUIN study update: analysis of the mechanisms of resistance to pirtobrutinib in CLL
Interprofessional Perspectives on Safety Management With Targeted Therapy for B-Cell Malignancies
Latest updates from the Phase I/II BRUIN study
Anthony Mato: LOXO-305 Demonstrates Efficacy in Patients With CLL/SLL
Clinical Pearl BTK Inhibitors and Pirtobrutinib
Update on the Phase I/II BRUIN study
Pirtobrutinib Non-Covalent BTK Inhibitor for Chronic Lymphocytic Leukemia (CLL) - BRUIN Study
